http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2714246-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3226ef2e62cab3eb1cd4933252bf91e7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
| filingDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0503f6838b0bf243797208e05dd5094d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6de241c02eea2746cf911894e4a4f533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_055c036192bef652b863605b01f59eb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76b7175381298cb4702c44347e82a83d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f55d587a6e94bb3da2ed24e31c6a8f1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb8a653d1cdcc9715282207697a4b4b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6041cad139b688720f121605d47da30a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c94df11df4c2dac6d531a7cf9e57069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79b713b7c1007d851430ea9a23ae7a90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0b2ae79205fbd8acdeee98d6fdd24ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9afc68937f70f771775a82fb9cd6d3d |
| publicationDate | 2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2714246-C1 |
| titleOfInvention | Monoclonal antibodies specific to different strains of influenza b virus |
| abstract | FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology. Described is a method of producing murine monoclonal antibodies specific to different strains of influenza virus B of Yamagata- and Victoria-lineage and having high specificity to NP-protein, comprising steps of producing antibody-producing splenocytes; murine myeloma cell accumulation; fusion of antibody-producing splenocytes with myeloma cells; selection of hybridomas; inoculating the hybridoma cells in the abdominal cavity of primed mice; accumulation of monoclonal antibodies in ascites; purification of obtained monoclonal antibodies. In the above method, for producing antibodies, a hybridoma-producing monoclonal antibody directed to NP-protein of influenza B virus, deposited as 6G1/B under RKKK(P) 785D (Russian collection of vertebrate cell cultures), or a hybridoma-producing monoclonal antibody directed to NP-protein of influenza B virus, deposited as 10A5/V under number RKKK(P) 787D in Specialized collection of cell cultures of the Collection of Vertebrate Cell Cultures Core facilities centre of the Federal Publicly Funded Institution of Science of the Institute of Cytology of the Russian Academy of Sciences.EFFECT: invention extends the range of methods for producing murine monoclonal antibodies specific for influenza virus B of Yamagata- and Victoria-lineage and having high specificity for NP-protein.3 cl, 8 dwg, 1 tbl, 5 ex |
| priorityDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 319.